SecBot SecBot

GNMSF

GENMAB A/S
OTC· Pharmaceutical Preparations· CIK 0001434265 Biotech & Drug Discovery
$447.55 +0.00 (+0.00%)
Oct 26 4:00 PM ET · prev $447.55
1 year
+50.6%
from $297.22 · Oct 27
30 days
+26.1%
from $355.00
52-week range
$232.34–447.55
0% from high · low Jun 2
Avg volume 20D
2.6K
Oct 6 spike 37.2K
Short interest
🔒 Subscribers only
Filing reports
10
analyzed by SecBot
SecBot read MIXED 5 reports · latest
Balance 0 bearish · 0 bullish · 5 neutral oldest → newest, height = score
Avg score ·High conf. 5/5
Strongest NEUTRAL This 6-K filing reports a routine insider sale by Board member Michael Kavanagh, who sold 526 shares at DKK…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • TrendUPTREND

    27% above its 50-day average. New closing high $447.55 on Oct 26.

Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
May 29, 2026 SEC
This 6-K filing reports a routine insider sale by Board member Michael Kavanagh, who sold 526 shares at DKK 1,734.75…
6-K — Impact 2/10
May 13, 2026 SEC
Genmab filed its updated Articles of Association as a 6-K, reflecting routine corporate governance updates including…
6-K — Impact 2/10
May 12, 2026 SEC
Genmab announced a nominal capital increase of 2,346 shares (0.004% of share capital) from employee warrant exercises…
6-K — Impact 1/10
Apr 1, 2026 Clinical trial readout
T-90d Trial Readout: Epcoritamab (Phase 2)
Trial: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large
Jun 26, 2024 Event
EPKINLY
Supplemental Approval — Efficacy — EPCORITAMAB-BYSP — INJECTABLE — SUBCUTANEOUS

Washington

Q3 2026 · filed Oct 20
Lobbying Q3 $160K +33.3% QoQ
YoY +33.3% vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
HCRHealth IssuesMMMMedicare/Medicaid
8 quarters Open in Washington ›

Corporate Lobbying

This company's lobbying spend, firms, issues and congressional activity are for subscribers.

Subscribe for Full Access

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
May 19, 2026
Clinical Trial
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Phase 2 · TERMINATED
Apr 1, 2026
Trial readout
T-90d Trial Readout: Epcoritamab (Phase 2)
Trial: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma Sponsor: Genmab Phase: Phase 2…
Mar 4, 2026
Clinical Trial
Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)
Phase 2 · TERMINATED
Jun 26, 2024
FDA
EPKINLY
Supplemental Approval — Efficacy — EPCORITAMAB-BYSP — INJECTABLE — SUBCUTANEOUS

SecBot reports

10 filings · 0 bullish · 0 bearish · 10 neutral
All GNMSF filing & press-release reports (10)